הלוואות ואשראי לטווח ארוך של החברה: Nektar (NKTR)

Nektar Therapeutics (NKTR) is a leading player in polymer engineering, developing high-tolerability oncology drugs through protein modification. Stock price fluctuations on GURU.Markets reflect the dynamics of an asset with a debt load of 0.13. The business relies on US-based capacities and proprietary platforms, while its resilience is ensured by its independence from global crises and stable demand for biotechnology.

This indicator measures the share of liabilities with a maturity of over one year within the capital structure, allowing for an assessment of long-term financial stability and the risk of shareholder value dilution. By analyzing the history of the firm's long-term borrowings, an investor can determine how critical debt accumulation is for Nektar Therapeutics (NKTR) amid the loss of B2B partners and the ecosystem's survival dependence on medical regulatory decisions.